Sleep Apnea Implants Market Report 2026

The sleep apnea implants market size has grown rapidly in recent years. It will grow from $0.6 billion in 2025 to $0.68 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to rising sleep apnea prevalence, cpap intolerance rates, growth in sleep disorder diagnosis, increase in obesity levels, expansion of sleep clinics.

The sleep apnea implants market size is expected to see rapid growth in the next few years. It will grow to $1.1 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to demand for long term implant therapy, growth in minimally invasive procedures, rising awareness of sleep health, expansion of reimbursement coverage, innovation in neurostimulation devices. Major trends in the forecast period include hypoglossal nerve stimulation devices, implantable airway support systems, programmable neurostimulation implants, minimally invasive sleep implants, wireless controlled implant platforms.

The rising prevalence of obesity is anticipated to drive the growth of the sleep apnea implants market in the coming years. Obesity is a medical condition characterized by an excessive accumulation of body fat that significantly increases the risk of adverse health outcomes and chronic diseases. Obesity is rising largely due to increasing consumption of calorie-dense, highly processed foods, which provide excess energy with low nutritional value and promote long-term weight gain. The expansion of obesity increases demand for sleep apnea implants, as excess fat around the neck and upper airway raises the risk and severity of obstructive sleep apnea, leading more patients who cannot tolerate CPAP therapy to require long-term implantable treatment solutions. For example, in May 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, an estimated 64% of adults aged 18 and above in England were classified as overweight or obese, with rates notably higher among men at about 69% compared to approximately 59% among women. Therefore, the rising prevalence of obesity is driving the growth of the sleep apnea implants market.

Companies operating in the sleep apnea implants market are focusing on technological innovation, such as hypoglossal nerve stimulation (HNS) therapy to enhance airway patency and reduce obstructive sleep apnea events. Hypoglossal nerve stimulation (HNS) therapy refers to an implantable medical intervention designed to treat obstructive sleep apnea by electrically stimulating the hypoglossal nerve, which controls tongue movements, to maintain airway openness during sleep. For example, in November 2025, Children’s Hospital of Pittsburgh, a US-based pediatric hospital, performed its first implantation of the Inspire V implant, featuring an integrated respiratory sensor that reduces the implanted system from three components to two, plus updated software that improves patient management efficiency and accessibility, with minimal recovery that typically requires one night of observation. The Inspire V implant system treats obstructive sleep apnea by stimulating the hypoglossal nerve to maintain an open airway during sleep, benefiting patients with a simplified two-component design and software that enhances therapy management and reduces procedural complexity.

In September 2023, Nyxoah SA, a Belgium-based medical technology company specializing in implantable hypoglossal nerve stimulation systems for obstructive sleep apnea (OSA), entered into a strategic partnership with ResMed. Through this collaboration, Nyxoah aims to expand market access and accelerate adoption of its Genio implantable sleep apnea therapy in Germany by leveraging ResMed’s established clinical, sales, and distribution infrastructure in the region. ResMed is a US-based provider of sleep and breathing health technologies with extensive experience in sleep disorder management.

Major companies operating in the sleep apnea implants market are Medtronic Plc, Koninklijke Philips N.V., Asahi Kasei Corporation, Nyxoah SA, Fisher & Paykel Healthcare Limited, LivaNova Plc, Contec Medical Systems Co. Ltd., Inspire Medical Systems Inc., Drive DeVilbiss Healthcare GmbH, Pillar Palatal LLC, SomnoMed Limited, Respicardia, Inc., Sibel Health Inc., LinguaFlex LLC, Advanced Brain Monitoring Inc, Cleveland Medical Devices Inc., Siesta Medical, Inc., Avery Biomedical Devices Inc., and Nox Medical, Somnowell Ltd.

Tariffs are impacting the sleep apnea implants market by increasing the cost of imported implant components, neurostimulation electronics, and surgical accessories. Higher duties are raising device prices across hypoglossal and phrenic nerve stimulator segments. Hospitals and surgical centers using imported implant systems are facing higher procurement expenses. Regions dependent on cross border medical device supply chains, especially in north america and europe, are seeing pricing pressure. Manufacturers are expanding localized assembly and regional supplier partnerships. Tariffs are also encouraging domestic production of implantable device components. This supports stronger regional medtech manufacturing capacity and supply stability.

The sleep apnea implants market research report is one of a series of new reports that provides sleep apnea implants market statistics, including sleep apnea implants industry global market size, regional shares, competitors with a sleep apnea implants market share, detailed sleep apnea implants market segments, market trends and opportunities, and any further data you may need to thrive in the sleep apnea implants industry. This sleep apnea implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sleep apnea implants are implantable medical devices created to treat sleep apnea by stimulating or stabilizing airway muscles or respiratory nerves to keep airways open during sleep. These devices apply electrical impulses or physical support to prevent airway collapse and normalize breathing patterns in individuals with obstructive or central sleep apnea. They are intended to deliver long-term therapeutic benefits for patients who cannot tolerate traditional treatments such as continuous positive airway pressure therapy.

The primary product types of sleep apnea implants include phrenic nerve stimulators, hypoglossal neurostimulation devices, bone screw implant systems, palatal implants, and the pillar procedure. Phrenic nerve stimulators refer to implants that deliver electrical stimulation to the phrenic nerve to regulate breathing patterns in patients with sleep apnea. These implants are used for indications such as central sleep apnea and obstructive sleep apnea. They are distributed through direct sales to hospitals, medical device distributors, and specialty medical suppliers, and are utilized by end users including hospitals and ambulatory surgical centers.

The sleep apnea implants market consists of sales of hypoglossal nerve stimulation implants, phrenic nerve stimulators, palatal implants, pillar procedure implants, bone screw implant systems, implantable pulse generators, leads, and related surgical accessories. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.